摘要
[目的]观察来曲唑和三苯氧胺治疗绝经后Ⅰ期乳腺癌患者术后的辅助治疗效果和不良反应。[方法]65例绝经后Ⅰ期乳腺癌患者术后给予内分泌辅助治疗,其中32例患者给予来曲唑;另33例给予三苯氧胺共5年。观察治疗效果和不良反应。[结果]来曲唑无病生存率明显高于三苯氧胺组(P=0.035),复发率明显低于三苯氧胺组(P=0.035),两组不良反应无显著性差异。[结论]来曲唑用于绝经后Ⅰ期乳腺癌患者术后的辅助治疗疗效优于三苯氧胺。
[Objective] To observe the assistance therapeutic effect and bad reaction of Letrozone and Tarnoxifen treating postmenopausal phase Ⅰ breast cancer after operation. [Method] Administer assistant incretion treatment to 65 cases,among which 32 orally take Letrozone; another 33 Tamoxifen,for 5 years. Observe their efficacy and bad reaction. [Result] The non-disease survival rate of Letrozole is obviously higher, the recurrent rate markedly lower than Tamoxifen group（P= 0. 035 ）, there＇s no marked difference on bad reaction between both groups. [Conclusion] Letrozone is better than Tamoxifen in assistant treatment to postmenopausal phaseⅠ breast cancer after operation.
出处
《浙江中医药大学学报》
CAS
2009年第1期63-64,共2页
Journal of Zhejiang Chinese Medical University
关键词
来曲唑
三苯氧胺
乳腺癌
内分泌治疗
Letrozone
Tamoxifen
phaseⅠ breast cancer
incretion treatment
